Apr 15 |
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
|
Apr 11 |
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
|
Apr 10 |
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
|
Apr 8 |
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
|
Apr 5 |
Theratechnologies Appoints Elina Tea to its Board of Directors
|
Apr 3 |
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
|
Mar 28 |
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
|
Mar 22 |
Theratechnologies Announces Update on its Preclinical Oncology Research Program
|
Mar 22 |
Theratechnologies Appoints Jordan Zwick to its Board of Directors
|
Mar 21 |
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
|